OLD Category: immuno-oncology

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123 Tumors

• Thokala R. et al.,

Validated PD-L1 immunohistochemistry assays (E1L3N & SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system

• Schats K.A. et al.,

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer

• Song I.H. et al.,

Immunologic heterogeneity of tumor infiltrating lymphocyte composition in primary melanoma

• Weiss S.A. et al.,

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

• Zaretsky J.M. et al.,

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

• Shukuya T et al.,

PD-1 blockade enhances the vaccination-induced immune response in glioma

• Antonios J.P. et al.,

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

• Armand P. et al.,

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer

• Herter-Sprie G.S. et al.,

Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade

• Chen P.L. et al.,

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma

• Mullane S.A. et. al.,

Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

• Gray M.J. et al.,